You just read:

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

News provided by

UCB, Inc.

May 20, 2019, 07:00 ET